Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, reported financial results and provided a corporate update for the third quarter ended September 30, 2022. Alpha Cognition also announced that it has withdrawn the marketed public offering of units previously announced on November 17, 2022. The company completed an additional steady state bioavailability-bioequivalence study which was designed to demonstrate pharmacokinetic (PK) equivalence between 5mg ALPHA-1062 delayed release tablets and 8 mg galantamine hydrobromide extended release (ER) capsules. The company continues to prepare its NDA filing for ALPHA-1062 for mild to moderate Alzheimer’s disease. If approved, it would be the first innovative oral therapy available for mild-to-moderate Alzheimer’s disease in over a decade.

Read the full press release here: Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update